Off-Label Use Explained

Off-label use means using an approved drug or peptide for a condition, dose, or population that is not in the approved indication. For example, an approved peptide might be studied for a different condition than the one for which it was approved.

Off-label prescribing is legal in many contexts, but it shifts responsibility to the prescriber to justify the use.

Off-label use of an approved peptide: the peptide is registered but prescribed outside its approved indication. Research use of an unapproved peptide: the peptide is not registered and is explicitly for research, not therapeutic use.

These are distinct legal and safety contexts.

If a doctor prescribes a peptide off-label, the doctor bears responsibility for justifying the use and monitoring safety. Off-label use is not inherently unethical — it can be appropriate when approved alternatives are unavailable and evidence supports the off-label use.

But it requires clinical judgment and evidence review.

Using a peptide for an unapproved indication means less safety data for that specific context. Dosing and monitoring protocols may be undefined. Adverse events may be unpredictable.

Off-label use is not the same as experimental access through SAS or clinical trials.